TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: patients with endovascular therapy: mTICI score 2b or better at initial angiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: no symptomatic intracranial hemorrhage at 24-36 hours
Endpoint domain: Adverse events/effects
Primary endpoint: PET2 assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour urinary protein quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Correlation of bone density with calcium deposited in coronary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Gastroduodenal Erosions and Ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pharmacokinetics of Intravitreal Aflibercept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of device-related events
Endpoint domain: Adverse events/effects
Primary endpoint: modified Ranking Scale (mRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Epigenetic modifications in circulating monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ST-segment resolution at 30 minutes post-PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infarction size at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glycemic level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average Daily In-Hospital Use of Opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Upper Extremity Score of the Fugl-Meyer Assessment (FM-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Absolute survival
Endpoint domain: Mortality/survival
Primary endpoint: Cytokine Response Score (CRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Develop Patform
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Change from baseline Biomarkers of Cardiovascular Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Persistent chronic post-thoracotomy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of consecutive incident dialysis patients that are eligible
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of eligible patients that will consent to randomization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of randomized patients that comply with their group assignment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Complete Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to optimal antimicrobial therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Cutibacterium Acnes levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reproducibility of DCE, T2* and DWI MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell culture growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of URAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Pressure Index (BPI) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and efficacy of PCP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure transmission ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Hoehn Yahr Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parkinson's Disease Questionnaire-PDQ 39
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Outcome percentage Phyla
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life in pancreatic cancer patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Numeric Pain Rating Scale (NPRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with DSA level below 1000MFI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tmax of ticagrelor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Bronchodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in FEV-1 % Predicted Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Remission of Crohn's Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: disease control rate: melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: disease control rate: renal cell cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Development of moderate or worse TR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Missed stones found
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Efficacy (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Blood Eosinophil Levels at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Who Achieved >=50% Eosinophil Repletion by Day 140
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) From Pre-dose (Day 1) to Day 140 for Mepolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autism diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-operation Rate
Endpoint domain: Adverse events/effects
Primary endpoint: pacing thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Opioid Overdose
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Daily Shoulder Pain With Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Score Within 5 Mins After Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative bleeding point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of overweight or obese children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development or Progression of Age-related Cataract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Undergoing Cataract Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AOPP Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatty mass percentage at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children neurological development at 2 years old
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Behaviorally Coded Challenging Behaviors (Agitated, Disruptive, Resistive)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Caregiver Health and Wellbeing - Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cmax of ulimorelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of ulimorelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual pleural effusion at chest X-Ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to first occurrence of Major Adverse Cardiovascular Event (MACE)
Endpoint domain: Mortality/survival
Primary endpoint: Mucosa recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Treatment-emergent and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Course of prealbumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Eligibility criteria scale
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bone mineral accrual
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proliferation rate measured by Ki-67
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rating by Primary Caregivers on Use and Relevance of Cry and Fuss Clock
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rating by Primary Caregiver on Level of Engagement with COOL Mobile App
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tumour margin status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Extrapancreatic infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in self-reported acute organophosphate poisoning symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasma Cholinesterase (PchE) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Client distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety and tolerability of PF-04308515
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in biochemical and metabolic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Scoring on the Quality of Recovery-15 Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Externalizing behavior problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Internalizing behavior problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: N-acetylaspartate/Creatine ratio in the motor cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: maximum tolerated dose of HFA-SRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Preeclampsia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percent Change in Eczema Area Severity Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Glucose AUC during 2H OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Current level of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Social Anxiety Scale (LSAS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of patients needing re-catheterization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maternal Stress Physiology as Measured by Change in Slope for Salivary Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anxiety Levels as Measured by the State Trait Anxiety Inventory-X2 (STAI-X2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Quality of Life as Measured by the EQ-5D5L Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Immunologic Data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Constipation Scoring System (Cleveland Criteria)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Survival on discharge from hospital in acceptable neurological state
Endpoint domain: Mortality/survival
Primary endpoint: Rate of post-operative administration of narcotics or rescue anti-nausea medications
Endpoint domain: Adverse events/effects
Primary endpoint: Readiness for discharge
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Incident pancreatic cancer
Endpoint domain: Mortality/survival
Primary endpoint: Safety analysis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in stroke index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Score in the Ages & Stages Questionnaires communication domain
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: GSK2141795 concentration in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fertility counseling satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post treatment decision making quality
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Reproductive history assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Social Anxiety Scale (LSAS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients on pharmacological regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: IBS QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: eradication of the infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: the rate of wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 30-day recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Clinically Acceptable Tidal Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Leads Overlap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of CD19-IL7/CCL19 CAR-T
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of pulse oximeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Current practices of upper limb rehabilitation after stroke
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Stroke survivors view on upper limb rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of postoperative pulmonary venous obstruction (PVO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Days of chest drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of Symptom Inner Restlessness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of Abemaciclib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average total number of headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Distress Intolerance Index (DII) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mirror-Tracing Persistence Task (MTPT) quit latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Marijuana Problems Scale (MPS) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Cannabis Use Disorder (CUD) diagnostic criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Timeline follow-back (TLFB) cannabis use frequency
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Marijuana Motives Measure (MMM) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum tolerated dose (MTD) of radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Performance - Trails B - Seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive Performance - Trails B - Errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incident Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction of abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum observed concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum urate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urine uric acid excretion amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Medication Appropriateness Index (MAI)-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anandamide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Center of pressure (COP) velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center of pressure excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful prolongation of pregnancy for 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Efficacy against culture-confirmed influenza-illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of cilengitide
Endpoint domain: Adverse events/effects
Primary endpoint: Total score from the FACT-GOG-Ntx questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Amount of minerals in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body Dysmorphic Disorder Examination
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Yale Brown Obsessive Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Body Dysmorphic Disorder Clinical Global Impressions Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and type of dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Annual increase in weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Device-related target lesion failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IKS (International Knee Society) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pharmacokinetics and markers of exploratory coagulation pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety and tolerability of interventions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Safe Dosing
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in number of MCV lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pharmacokinetics of licarbazepine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidant imbalance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events following administration of allogeneic MSCs
Endpoint domain: Adverse events/effects
Primary endpoint: Total number of attempts for successful cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in antibody titer to tetanus, diphtheria, pertussis antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fraction of EGFR+ NSCLC patients with sequential TKI treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum RANKL concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression score on cognitive training task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ICIQ-MLUTS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: sebaceous gland activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: changes in skin morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinical Benefit Rate at 16 Weeks (CBR-16)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Auralya
Endpoint domain: Adverse events/effects
Primary endpoint: Performance of Auralya
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD11b and CD56 marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Days Cocaine Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status